BSD Medical Obtains Patent License for Primary Breast Cancer Treatment System from Duke University
Complete the form below to unlock access to ALL audio articles.
BSD Medical Corp. has announced that the company has signed an exclusive patent license agreement with Duke University for rights to Duke’s treatment system for primary breast cancer using hyperthermia therapy.
This breast treatment system has been used and tested at Duke University Medical Center over several years. BSD intends to integrate this technology with its current BSD-2000 and BSD-500 hyperthermia systems. The technology will be used to complement radiation therapy, chemotherapy, and heat released, targeted liposome drug delivery.
One of BSD Medical’s areas of focus is breast cancer (the number one cancer contracted by women), and BSD has been rapidly expanding the breadth of its technologies for breast cancer treatment.
